An adipose tissue-independent insulin-sensitizing action of telmisartan: A study in lipodystrophic mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 331, Issue 3, 2009, Pages 1096-1103

  Rong, X ^a   Li, Yuhao ^a   Ebihara, K ^a   Zhao, M ^a   Aini, W ^a   Kusakabe, T ^a   Hirata, M ^a   Miyamoto, L ^a   Murray, M ^b   Nakao, K ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b University of Sydney   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CORTICOSTERONE; FAT DROPLET; FATTY ACID; GLUCOSE; INSULIN; LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TELMISARTAN; TRIACYLGLYCEROL; A ZIP PROTEIN, MOUSE; A-ZIP PROTEIN, MOUSE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; TRANSCRIPTION FACTOR;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; FATTY LIVER; FEMALE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HOMEOSTASIS; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; LIPODYSTROPHY; MOUSE; NONHUMAN; PRIORITY JOURNAL; UPREGULATION; ANIMAL; DISEASE MODEL; DRUG EFFECT; DRUG POTENTIATION; ENERGY METABOLISM; GENETICS; GLUCOSE TOLERANCE TEST; LIVER; METABOLISM; ORGAN SIZE; PATHOLOGY; TRANSGENIC MOUSE;

ADIPOSE TISSUE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; BLOOD GLUCOSE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENERGY METABOLISM; FEMALE; GLUCOSE TOLERANCE TEST; INSULIN; INSULIN RESISTANCE; LIPODYSTROPHY; LIVER; MICE; MICE, TRANSGENIC; ORGAN SIZE; PPAR GAMMA; TRANSCRIPTION FACTORS; TRIGLYCERIDES;

EID: 73349114915     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.157099     Document Type: Article

References (33)

1. Agarwal AK and Garg A (2006) Genetic basis of lipodystrophies and management of metabolic complications. Annu Rev Med 57:297-311.
2. Araki K, Masaki T, Katsuragi I, Tanaka K, Kakuma T, and Yoshimatsu H (2006) Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice. Hypertension 48:51-57.
3. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, and Kurtz TW (2004) Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43:993-1002.
4. Berg AH and Scherer PE (2005) Adipose tissue, inflammation, and cardiovascular disease. Circ Res 96:939-949.
5. Bergman RN and Ader M (2000) Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends Endocrinol Metab 11:351-356.
6. Boden G (1997) Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46:3-10.
7. Chao L, Marcus-Samuels B, Mason MM, Moitra J, Vinson C, Arioglu E, Gavrilova O, and Reitman ML (2000) Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J Clin Invest 106:1221-1228.
8. Charles MA, Eschwège E, Thibult N, Claude JR, Warnet JM, Rosselin GE, Girard J, and Balkau B (1997) The role of non-esterified fatty acids in the deterioration of glucose tolerance in Caucasian subjects: results of the Paris Prospective Study. Diabetologia 40:1101-1106.
9. Cusin I, Zakrzewska KE, Boss O, Muzzin P, Giacobino JP, Ricquier D, Jeanrenaud B, and Rohner-Jeanrenaud F (1998) Chronic central leptin infusion enhances insulin-stimulated glucose metabolism and favors the expression of uncoupling proteins. Diabetes 47:1014-1019.
10. Ebihara K, Ogawa Y, Masuzaki H, Shintani M, Miyanaga F, Aizawa-Abe M, Hayashi T, Hosoda K, Inoue G, Yoshimasa Y, et al. (2001) Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipoatrophic diabetes. Diabetes 50:1440-1448.
11. Engeli S, Schling P, Gorzelniak K, Boschmann M, Janke J, Ailhaud G, Teboul M, Massiéra F, and Sharma AM (2003) The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? Int J Biochem Cell Biol 35:807-825.
12. Evans RM, Barish GD, and Wang YX (2004) PPARs and the complex journey to obesity. Nat Med 10:355-361.
13. Flier JS (1997) Leptin expression and action: new experimental paradigms. Proc Natl Acad Sci U S A 94:4242-4245.
14. Fujimoto M, Masuzaki H, Tanaka T, Yasue S, Tomita T, Okazawa K, Fujikura J, Chusho H, Ebihara K, Hayashi T, et al. (2004) An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett 576:492-497.
15. Garg A (2004) Acquired and inherited lipodystrophies. N Engl J Med 350:1220-1234.
16. Gavrilova O, Haluzik M, Matsusue K, Cutson JJ, Johnson L, Dietz KR, Nicol CJ, Vinson C, Gonzalez FJ, and Reitman ML (2003) Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem 278:34268-34276.
17. Haluzik M, Dietz KR, Kim JK, Marcus-Samuels B, Shulman GI, Gavrilova O, and Reitman ML (2002) Adrenalectomy improves diabetes in A-ZIP/F-1 lipoatrophic mice by increasing both liver and muscle insulin sensitivity. Diabetes 51:2113-2118.
18. Honjo S, Nichi Y, Wada Y, Hamamoto Y, and Koshiyama H (2005) Possible beneficial effect of telmisartan on glycemic control in diabetic subjects. Diabetes Care 28:498.
19. Liu L, Karkanias GB, Morales JC, Hawkins M, Barzilai N, Wang J, and Rossetti L (1998) Intracerebroventricular leptin regulates hepatic but not peripheral glucose fluxes. J Biol Chem 273:31160-31167.
20. Lorenzo O, Ruiz-Ortega M, Suzuki Y, Rupérez M, Esteban V, Sugaya T, and Egido J (2002) Angiotensin III activates nuclear transcription factor-kappaB in cultured mesangial cells mainly via AT(2) receptors: studies with AT(1) receptor-knockout mice. J Am Soc Nephrol 13:1162-1171.
21. Miura Y, Yamamoto N, Tsunekawa S, Taguchi S, Eguchi Y, Ozaki N, and Oiso Y (2005) Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: Metabolic and antiatherogenic consequences. Diabetes Care 28:757-758.
22. Moitra J, Mason MM, Olive M, Krylov D, Gavrilova O, Marcus-Samuels B, Feigenbaum L, Lee E, Aoyama T, Eckhaus M, et al. (1998) Life without white fat: a transgenic mouse. Genes Dev 12:3168-3181.
23. Neschen S, Morino K, Hammond LE, Zhang D, Liu ZX, Romanelli AJ, Cline GW, Pongratz RL, Zhang XM, Choi CS, et al. (2005) Prevention of hepatic steatosis and hepatic insulin resistance in mitochondrial acyl-CoA:glycerol-sn-3- phosphate acyltransferase 1 knockout mice. Cell Metab 2:55-65.
24. Oakes ND, Thalén PG, Jacinto SM, and Ljung B (2001) Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. Diabetes 50:1158-1165.
25. Pershadsingh HA and Kurtz TW (2004) Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease. Diabetes Care 27:1015.
26. Pilkis SJ and Granner DK (1992) Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis. Annu Rev Physiol 54:885-909.
27. Prasad A and Quyyumi AA (2004) Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation 110:1507-1512.
28. Ran J, Hirano T, and Adachi M (2004) Angiotensin II type 1 receptor blocker ameliorates overproduction and accumulation of triglyceride in the liver of Zucker fatty rats. Am J Physiol Endocrinol Metab 287:E227- E232.
29. Roberge C, Carpentier AC, Langlois MF, Baillargeon JP, Ardilouze JL, Maheux P, and Gallo-Payet N (2007) Adrenocortical dysregulation as a major player in insulin resistance and onset of obesity. Am J Physiol Endocrinol Metab 293:E1465-E1478.
30. Savage DB, Choi CS, Samuel VT, Liu ZX, Zhang D, Wang A, Zhang XM, Cline GW, Yu XX, Geisler JG, et al. (2006) Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J Clin Invest 116:817-824.
31. Shimabukuro M, Koyama K, Chen G, Wang MY, Trieu F, Lee Y, Newgard CB, and Unger RH (1997) Direct antidiabetic effect of leptin through triglyceride depletion of tissues. Proc Natl Acad Sci U S A 94:4637-4641.
32. Sugimoto K, Qi NR, Kazdová L, Pravenec M, Ogihara T, and Kurtz TW (2006) Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 47:1003-1009.
33. Takemori K, Gao YJ, Ding L, Lu C, Su LY, An WS, Vinson C, and Lee RM (2007) Elevated blood pressure in transgenic lipoatrophic mice and altered vascular function. Hypertension 49:365-372.